Diminished Aβ (1–42) (Aβ42), elevated phosphorylated tau (p-tau), and total tau (t-tau) in the cerebral spinal fluid (CSF) were well acknowledged as diagnostic biomarkers for AD research (Jack et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.